leadf
logo-loader
view4D pharma PLC

4d pharma reveals 'phenomenal results' from early stage cancer trial

4d pharma plc's (LON:DDDD) Duncan Peyton talks to Proactive London following the positive results of its clinical results in the first part of a trial on very poorly patients battling cancer.

The trial of its live biotherapeutic in combination with an established cancer drug called a checkpoint inhibitor resulted in five people, or 42% of the group, experiencing a clinically meaningful benefit from the two drugs.

Peyton explains how this is the first time live biotheroputics have been used in this way and without any side effects.

Quick facts: 4D pharma PLC

Price: 128 GBX

LSE:DDDD
Market: LSE
Market Cap: £168.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma PLC named herein, including the promotion by the Company of 4D pharma PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

4d pharma says Merck KGaA and Pfizer cancer collaboration is 'big step forward'

4D pharma PLC's (LON:DDDD) chief executive Duncan Peyton talks to Proactive London's Katie Pilbeam about the clinical trial collaboration and supply agreement with Merck KGaA, and Pfizer Inc. Peyton says 'it's another step forward in how we work and expand our oncology franchise' which will...

3 weeks, 2 days ago

2 min read